Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit

This article was originally published in The Pink Sheet Daily

Executive Summary

NIH's early termination of the AIM-HIGH trial does further damage to combination therapy for increasing HDL cholesterol and lowering triglycerides in patients with well-controlled LDL cholesterol.

You may also be interested in...



Merck Calls It Quits On Anacetrapib

Despite success in REVEAL outcomes trial, Merck will not submit the for the cholesteryl ester transfer protein (CETP) inhibitor for regulatory approval.

Merck Calls It Quits On Anacetrapib

Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.

New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials

The cardiology community is increasingly questioning the value of adding on a variety of lipid therapies to treatment with highly effective statins, based on accumulating evidence of the lack of value of affecting cholesterol parameters other than LDL.

Related Content

Topics

UsernamePublicRestriction

Register

PS072294

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel